Oncimmune (LON:ONC) Posts Earnings Results

Oncimmune (LON:ONCGet Free Report) announced its quarterly earnings data on Monday. The company reported GBX (4.72) (($0.06)) earnings per share for the quarter, Digital Look Earnings reports. Oncimmune had a net margin of 586.08% and a negative return on equity of 760.96%.

Oncimmune Stock Performance

Shares of ONC opened at GBX 9.45 ($0.12) on Monday. Oncimmune has a 12-month low of GBX 8 ($0.10) and a 12-month high of GBX 31 ($0.38). The stock has a market cap of £7.01 million, a P/E ratio of -315.00 and a beta of 1.19. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 806.85. The company has a 50-day moving average of GBX 13.48 and a two-hundred day moving average of GBX 14.81.

About Oncimmune

(Get Free Report)

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.

Further Reading

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.